Oculis Holding AG Ordinary shares (OCS) - Net Assets
Based on the latest financial reports, Oculis Holding AG Ordinary shares (OCS) has net assets worth $196.29 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($236.23 Million) and total liabilities ($39.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Oculis Holding AG Ordinary shares to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $196.29 Million |
| % of Total Assets | 83.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 94.6 |
Oculis Holding AG Ordinary shares - Net Assets Trend (2020–2025)
This chart illustrates how Oculis Holding AG Ordinary shares's net assets have evolved over time, based on quarterly financial data. See OCS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Oculis Holding AG Ordinary shares (2020–2025)
The table below shows the annual net assets of Oculis Holding AG Ordinary shares from 2020 to 2025. For live valuation and market cap data, see Oculis Holding AG Ordinary shares stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $196.29 Million | +167.49% |
| 2024-12-31 | $73.38 Million | -21.71% |
| 2023-12-31 | $93.73 Million | +195.65% |
| 2022-12-31 | $-97.99 Million | -60.76% |
| 2021-12-31 | $-60.95 Million | -39.63% |
| 2020-12-31 | $-43.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oculis Holding AG Ordinary shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33122280900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $587.67K | 0.30% |
| Other Comprehensive Income | $28.31 Million | 14.42% |
| Other Components | $552.35 Million | 281.39% |
| Total Equity | $196.29 Million | 100.00% |
Oculis Holding AG Ordinary shares Competitors by Market Cap
The table below lists competitors of Oculis Holding AG Ordinary shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Jindun Fans Co Ltd
SHE:300411
|
$655.54 Million |
|
CeriBell, Inc
NASDAQ:CBLL
|
$655.65 Million |
|
YIDU TECH INC. DL -00002
F:0EL
|
$655.70 Million |
|
Sinoma Energy Conservation Ltd
SHG:603126
|
$655.72 Million |
|
TSEC Corp
TW:6443
|
$655.12 Million |
|
Akfen Yenilenebilir Enerji A.S.
IS:AKFYE
|
$655.07 Million |
|
ECOVE Environment Corp
TWO:6803
|
$654.64 Million |
|
Heritage Insurance Hldgs Inc
NYSE:HRTG
|
$654.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oculis Holding AG Ordinary shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 73,383,000 to 196,292,736, a change of 122,909,736 (167.5%).
- Net loss of 94,508,181 reduced equity.
- New share issuances of 178,859,000 increased equity.
- Other comprehensive income increased equity by 30,809,117.
- Other factors increased equity by 7,749,800.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-94.51 Million | -48.15% |
| Share Issuances | $178.86 Million | +91.12% |
| Other Comprehensive Income | $30.81 Million | +15.7% |
| Other Changes | $7.75 Million | +3.95% |
| Total Change | $- | 167.49% |
Book Value vs Market Value Analysis
This analysis compares Oculis Holding AG Ordinary shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-1.33 | $11.30 | x |
| 2021-12-31 | $-1.86 | $11.30 | x |
| 2022-12-31 | $-2.99 | $11.30 | x |
| 2023-12-31 | $3.13 | $11.30 | x |
| 2024-12-31 | $1.82 | $11.30 | x |
| 2025-12-31 | $3.75 | $11.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oculis Holding AG Ordinary shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -48.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.20x
- Recent ROE (-48.15%) is below the historical average (-43.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -1497.78% | 0.06x | 0.00x | $-10.51 Million |
| 2021 | 0.00% | -1932.50% | 0.02x | 0.00x | $-12.46 Million |
| 2022 | 0.00% | -4243.20% | 0.02x | 0.00x | $-28.90 Million |
| 2023 | -94.74% | -10056.85% | 0.01x | 1.22x | $-98.17 Million |
| 2024 | -116.89% | -12503.94% | 0.01x | 1.64x | $-93.12 Million |
| 2025 | -48.15% | 0.00% | 0.00x | 1.20x | $-114.14 Million |
Industry Comparison
This section compares Oculis Holding AG Ordinary shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oculis Holding AG Ordinary shares (OCS) | $196.29 Million | 0.00% | 0.20x | $655.22 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candida… Read more